Showing results (151-160 of 163) with videos related to
Sort By:
Pageof 17
Liver International : Official Journal of the International Association for the Study of the Liver|July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.Journal of Cancer Research and Clinical Oncology|March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patientsMargherita Rimini, Mara Persano, Toshifumi Tada, et al.Targeted Oncology|March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini, Mara Persano, Toshifumi Tada, et al.International Journal of Cancer|November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaFederico Rossari, Toshifumi Tada, Goki Suda, et al.Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.Targeted Oncology|April 30, 2024
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.Targeted Oncology|January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular CarcinomaSilvia Camera, Margherita Rimini, Federico Rossari, et al.European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.Liver Cancer|September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter StudyFederico Rossari, Toshifumi Tada, Goki Suda, et al.Pageof 17